Study	Reason for exclusion
Chang 1998	Case series study of 4 adult patients with NCC with epilepsy. Tiagabine HCL was used as an add‐on drug in 4 patients (2 on carbamazepine and 2 on phenytoin).
Kaushal 2006	Comparison of clobazam with phenytoin sodium for prevention of seizures in people with single NCC. This is an underpowered study which was prematurely terminated due to relocation of one of the authors. The reason for the difference in numbers between the two comparison groups is not clear. It is not clear whether the two groups were balanced as far as the prognostic variables are concerned. The number of participants randomised to phenytoin and clobazam differ in the text and in the CONSORT flow chart. The study planned to enrol 135 participants in each of the two groups, in order to provide sufficient power to detect 10% difference in the primary outcome measure with 90% confidence. The numbers accrued, however fell short on account of premature termination of the study.
Lanchote 2002	The objective of this study was to determine the interaction between the AEDs and the selective metabolism of albendazole. In this study plasma concentrations of albendazole sulfoxide (ASOX) and albendazole sulphone (ASON) metabolites were measured in 32 adults who received phenytoin, carbamazepine, phenobarbital or no AED. None of the primary or secondary outcome measures in this review were assessed.

AED: antiepileptic drug
 HCL: hydrochloride
 NCC: neurocysticercosis